Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | AXL | P30530 | 2/20 | 0.49 |
| ▸ | CDK8 | P49336 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 2/20 | 0.41 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.41 |
| ▸ | PRKACA | P17612 | 2/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
| ▸ | CHUK | O15111 | 1/20 | 0.41 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | PAK4 | O96013 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16416975 | 0.96 | AXL (0.50) | BRD4MAPK1AXLCDK8RAB9A | |
| SCHEMBL31065010 | 0.81 | RIPK1 (0.54) | BRD4MAPK1RAB9AKMT2AMEN1 | |
| SCHEMBL16417014 | 0.81 | MAPK1 (0.54) | BRD4MAPK1AXLRAB9AKMT2A | |
| SCHEMBL23170079 | 0.80 | MAPK1 (0.59) | BRD4MAPK1AXLNUDT1JAK3 | |
| SCHEMBL16417000 | 0.77 | BRD4 (0.61) | BRD4MAPK1RAB9AKMT2AMEN1 | |
| SCHEMBL16417052 | 0.77 | BRD4 (0.50) | BRD4ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL23110560 | 0.77 | BRD4 (0.50) | BRD4MAPK1AXLNUDT1CDK9 | |
| SCHEMBL1820093 | 0.77 | CTSS (0.51) | BRD4RAB9AKMT2AMEN1NPC1 | |
| SCHEMBL16417049 | 0.74 | CYP1A2 (0.49) | BRD4AXLRAB9ANUDT1JAK2 | |
| SCHEMBL29802407 | 0.74 | BRD4 (0.48) | BRD4RAB9AIKBKBCHUKCDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002372-A1 | AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) | 2023-01-05 | — | — | US | disclosed |
| EP-3416960-B1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2021-12-01 | — | — | EP | disclosed |
| EP-3416960-B1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2021-12-01 | — | — | EP | disclosed |
| CN-108699035-B | Novel compounds | 特殊治疗有限公司 | 2021-10-15 | — | — | CN | disclosed |
| WO-2021062316-A1 | AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| US-10640498-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2020-05-05 | — | — | US | disclosed |
| US-10640498-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2020-05-05 | — | — | US | disclosed |
| US-20190055232-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LIMITED (GB) | 2019-02-21 | — | — | US | disclosed |
| US-20190055232-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LIMITED (GB) | 2019-02-21 | — | — | US | disclosed |
| US-10183013-B2 | Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway | NANT HOLDINGS IP, LLC (US) | 2019-01-22 | — | — | US | disclosed |
| CN-103391936-B | Carcinostatic agent | THE UNIVERSITY OF TOKYO (JP) | 2016-04-27 | — | — | CN | disclosed |
| EP-2565192-B9 | ANTICANCER AGENT | UNIV TOKYO (JP) | 2015-11-25 | — | — | EP | disclosed |
| US-9156827-B2 | Anticancer agent | THE UNIVERSITY OF TOKYO (JP) | 2015-10-13 | — | — | US | disclosed |
| US-9156827-B2 | Anticancer agent | THE UNIVERSITY OF TOKYO (JP) | 2015-10-13 | — | — | US | disclosed |
| EP-2565192-B1 | ANTICANCER AGENT | UNIV TOKYO (JP) | 2015-08-12 | — | — | EP | disclosed |
| WO-2015011008-A1 | 7-AZAINDOLE DERIVATIVES AS PARP INHIBITORS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2015-01-29 | — | — | WO | disclosed |
| CN-103391936-A | Anticancer agent | NAT UNIV CORP UNIV TOKYO | 2013-11-13 | — | — | CN | disclosed |
| US-20130102776-A1 | ANTICANCER AGENT | RIKEN (JP) | 2013-04-25 | — | — | US | disclosed |
| US-20130102776-A1 | ANTICANCER AGENT | RIKEN (JP) | 2013-04-25 | — | — | US | disclosed |
| EP-2565192-A1 | ANTICANCER AGENT | The University of Tokyo (JP) | 2013-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183013-B2 | Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway | SMO, SHH, SOS1 | BRD4 850/4885MAPK1 207/4885AXL 1062/4885 |
| US-10640498-B2 | Compounds | USP30, USP20, UBQLN1 | BRD4 1748/4885MAPK1 2307/4885AXL 3875/4885 |
| US-20190055232-A1 | NOVEL COMPOUNDS | USP30, USP20, USP28 | BRD4 1498/4885MAPK1 2160/4885AXL 3749/4885 |
| US-20230002372-A1 | AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | AZI2, AADAC, TPMT | BRD4 38/4885MAPK1 3325/4885AXL 2180/4885 |
| US-20130102776-A1 | ANTICANCER AGENT | PIM1, PIM3, PIM2 | BRD4 341/4885MAPK1 64/4885AXL 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.